## AMGN: Amgen Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.0% below STRENGTH zone (3.0-6.0%); PEG 1.02 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($317.35)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Amgen Stock (AMGN) News Today: Trump Drug‑Price Deals, Analyst Forecasts, and What to Watch Next — Dec. 22, 2025**
- Source: ts2.tech | 20251222T180808 | Somewhat-Bullish | Relevance: 100%
- Amgen Inc. (NASDAQ: AMGN) is currently under investor scrutiny due to new White House drug-pricing agreements, notably a "most-favored-nation" (MFN) push, and potential impacts on 2026 earnings. Analysts suggest these deals might be more about political and tariff uncertainty reduction than immediate profit compression. The stock traded higher despite these developments, driven by strong Q3 2025 earnings and promising pipeline developments in obesity and oncology, though MFN policies and pipeline risks remain key considerations for investors.

**2. Sarasin & Partners LLP Buys 47,873 Shares of Amgen Inc. $AMGN**
- Source: MarketBeat | 20251221T130935 | Bullish | Relevance: 100%
- Sarasin & Partners LLP increased its stake in Amgen Inc. by 7.8% in Q3, purchasing 47,873 shares to reach a total of 659,993 shares, valued at $180.82 million. This makes Amgen its 24th largest holding, representing about 1.8% of its portfolio. Amgen recently reported strong earnings, beating analyst expectations, and increased its quarterly dividend to $2.52 per share, resulting in a 3.1% yield.

**3. Amgen Stock (AMGN) News Today: TrumpRx Drug-Price Deal, FDA Approvals, Dividend Update, and 2026 Analyst Forecasts**
- Source: ts2.tech | 20251220T171830 | Somewhat-Bullish | Relevance: 100%
- Amgen Inc. (NASDAQ: AMGN) is navigating a complex landscape of policy changes, including a new drug-pricing deal with the Trump administration that offers pricing concessions for tariff relief. The company has also received significant FDA approvals for UPLIZNA and IMDELLTRA, strengthening its growth prospects and pipeline, while reaffirming its dividend for Q1 2026. Analysts present a split outlook for Amgen's stock in 2026, reflecting both pipeline potential and ongoing policy risks.

**4. Amgen’s Long-Term Pediatric Psoriasis Study on Apremilast: Why the Latest Update Matters for Investors**
- Source: TipRanks | 20251222T163506 | Somewhat-Bullish | Relevance: 100%
- Amgen (AMGN) has provided an update on its long-term Phase 3b clinical study of apremilast for pediatric plaque psoriasis, which aims to assess its long-term safety and efficacy in children aged 6 to 17. The study's status is now listed as completed, though data cleaning and reporting are reportedly ongoing, with no public results yet available. A positive outcome could bolster apremilast's market position against competitors like Novartis and Eli Lilly, supporting label expansion and investor confidence in the drug's long-term value within Amgen's inflammation portfolio.

**5. Matrix Asset Advisors Inc. NY Purchases 4,633 Shares of Amgen Inc. $AMGN**
- Source: MarketBeat | 20251222T122804 | Bullish | Relevance: 100%
- Matrix Asset Advisors Inc. NY has increased its stake in Amgen Inc. by 4.6%, purchasing an additional 4,633 shares and bringing its total holdings to 106,231 shares valued at approximately $29.98 million. This comes as Amgen reports strong quarterly earnings, beating analyst expectations with an EPS of $5.64 and revenue of $9.56 billion, and recently increased its quarterly dividend to $2.52 per share. Institutional investors collectively own 76.5% of Amgen's stock, and analysts maintain a "Moderate Buy" consensus rating with a price target of $332.85.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $304 | $329 | -8% |
| 2025-12-10 | Wells Fargo | $325 | $300 | +8% |
| 2025-12-03 | BMO Capital | $372 | $335 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |
| 2025-12-03 | BMO Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.00M) |
| Sells | 7 ($2.74M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.3%)
- Blackrock Inc.: 8.6% (-1.2%)
- State Street Corpora: 5.4% (-0.2%)
- Capital Internationa: 3.6% (+1.5%)
- Capital World Invest: 3.5% (+11.5%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.02 suggests fair value with growth premium. Forward P/E 15.1x stretched relative to 3% growth. Quality metrics strong (ROE 82%, margin 20%). Balance sheet: $4.2B free cash flow. Analyst sentiment positive (2 raises, avg +10%). Insider selling cluster ($2.7M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $178.4B |
| Beta | 0.45 |
| 52W Range | $257.05 - $346.38 |
| Short Interest | 2.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.02 |
| Forward P/E | 15.1 |
| Current P/E | 15.6 |
| YoY Growth | 3.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at 2.0% (minimal 5-day change). Below STRENGTH zone by 1.0pp (needs >3.0% for momentum thesis). MRS_5 (-0.1%) diverging from MRS_10 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.82), momentum weakening. RSI neutral at 56. OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.98% (CS: 81) | Neutral |
| RSI_14 | 55.5 | Neutral |
| MACD Histogram | -0.82 | Bearish |
| vs SMA20 | 1.004x | Above |
| vs SMA50 | 1.039x | Above |
| vs SMA200 | 1.115x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $331.39
- **Stop Loss:** $317.35 (4.2% risk)
- **Target:** $345.43 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 85
- **Position Value:** $28,168.15
- **Portfolio %:** 28.17%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-03 (Est: $4.74)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.01 | $5.64 | +12.5% |
| 2025Q2 | $5.28 | $6.02 | +14.1% |
| 2025Q1 | $4.26 | $4.90 | +15.0% |
| 2024Q4 | $5.08 | $5.31 | +4.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*